A detailed history of Tower Research Capital LLC (Trc) transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 541 shares of ALNY stock, worth $134,595. This represents 0.0% of its overall portfolio holdings.

Number of Shares
541
Previous 973 44.4%
Holding current value
$134,595
Previous $236,000 37.29%
% of portfolio
0.0%
Previous 0.0%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$233.81 - $287.01 $101,005 - $123,988
-432 Reduced 44.4%
541 $148,000
Q2 2024

Aug 13, 2024

SELL
$143.31 - $247.0 $109,202 - $188,214
-762 Reduced 43.92%
973 $236,000
Q1 2024

May 15, 2024

SELL
$146.51 - $198.2 $723,319 - $978,513
-4,937 Reduced 74.0%
1,735 $259,000
Q4 2023

Feb 13, 2024

BUY
$151.41 - $196.57 $239,530 - $310,973
1,582 Added 31.08%
6,672 $1.28 Million
Q3 2023

Nov 14, 2023

SELL
$170.77 - $211.65 $765,220 - $948,403
-4,481 Reduced 46.82%
5,090 $901,000
Q2 2023

Aug 14, 2023

BUY
$185.01 - $212.05 $1.65 Million - $1.89 Million
8,895 Added 1315.83%
9,571 $1.82 Million
Q1 2023

May 09, 2023

SELL
$182.66 - $235.53 $113,249 - $146,028
-620 Reduced 47.84%
676 $135,000
Q4 2022

Feb 10, 2023

SELL
$185.53 - $241.31 $291,838 - $379,580
-1,573 Reduced 54.83%
1,296 $308,000
Q3 2022

Nov 10, 2022

SELL
$138.54 - $232.0 $1.5 Million - $2.51 Million
-10,801 Reduced 79.01%
2,869 $575,000
Q2 2022

Aug 15, 2022

SELL
$120.42 - $169.29 $55,995 - $78,719
-465 Reduced 3.29%
13,670 $1.99 Million
Q1 2022

May 12, 2022

BUY
$127.18 - $173.91 $941,640 - $1.29 Million
7,404 Added 110.0%
14,135 $2.31 Million
Q4 2021

Feb 14, 2022

BUY
$159.56 - $209.29 $931,032 - $1.22 Million
5,835 Added 651.23%
6,731 $1.14 Million
Q3 2021

Nov 15, 2021

SELL
$169.75 - $207.73 $200,644 - $245,536
-1,182 Reduced 56.88%
896 $169,000
Q2 2021

Aug 16, 2021

BUY
$128.63 - $176.89 $102,003 - $140,273
793 Added 61.71%
2,078 $352,000
Q1 2021

May 17, 2021

SELL
$126.83 - $175.69 $877,283 - $1.22 Million
-6,917 Reduced 84.33%
1,285 $181,000
Q4 2020

Feb 16, 2021

BUY
$122.97 - $147.0 $476,385 - $569,478
3,874 Added 89.51%
8,202 $1.07 Million
Q3 2020

Nov 16, 2020

BUY
$121.19 - $165.49 $350,360 - $478,431
2,891 Added 201.18%
4,328 $631,000
Q2 2020

Aug 13, 2020

BUY
$104.21 - $156.44 $147,144 - $220,893
1,412 Added 5648.0%
1,437 $213,000
Q1 2020

May 15, 2020

SELL
$93.12 - $133.99 $143,870 - $207,014
-1,545 Reduced 98.41%
25 $3,000
Q4 2019

Feb 07, 2020

BUY
$74.51 - $124.23 $116,980 - $195,041
1,570 New
1,570 $181,000
Q3 2019

Nov 05, 2019

SELL
$70.9 - $87.82 $58,705 - $72,714
-828 Closed
0 $0
Q2 2019

Aug 13, 2019

BUY
$65.86 - $92.79 $44,521 - $62,726
676 Added 444.74%
828 $60,000
Q1 2019

May 14, 2019

BUY
$72.76 - $93.45 $11,059 - $14,204
152 New
152 $14,000
Q4 2018

Feb 14, 2019

SELL
$62.67 - $88.33 $81,094 - $114,299
-1,294 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$87.52 - $122.67 $100,210 - $140,457
1,145 Added 768.46%
1,294 $113,000
Q2 2018

Aug 15, 2018

SELL
$88.31 - $107.8 $478,640 - $584,276
-5,420 Reduced 97.32%
149 $15,000
Q1 2018

May 15, 2018

BUY
$115.92 - $148.54 $645,558 - $827,219
5,569 New
5,569 $663,000

Others Institutions Holding ALNY

About ALNYLAM PHARMACEUTICALS, INC.


  • Ticker ALNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 123,028,000
  • Market Cap $30.6B
  • Description
  • Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...
More about ALNY
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.